What is the future of CCR5 antagonists in rheumatoid arthritis?

被引：8

作者：

Takeuchi, Tsutomu ^{[1
]}

Kameda, Hideto ^{[1
]}

机构：

[1] Keio Univ, Div Rheumatol, Dept Internal Med, Sch Med,Shinjyu Ku, Toky 1608582, Japan

来源：

ARTHRITIS RESEARCH & THERAPY | 2012年 / 14卷 / 02期

关键词：

DOUBLE-BLIND; CHEMOKINE; RECEPTORS; BLOCKADE; TRIAL;

D O I：

10.1186/ar3775

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Fleishaker and colleagues reported on a double-blind placebo controlled clinical trial of a C-C chemokine-receptor type 5 (CCR5) antagonist, maraviroc, in rheumatoid arthritis (RA) patients with inadequate response to methotrexate, showing that it was ineffective. Two additional CCR5 antagonists, SCH351125 and AZD5672, also failed to demonstrate clinical efficacy. In addition, CCR5-blocking antibodies could not inhibit synovial fluid-induced monocyte chemotaxis. Thus, CCR5 appears not to be a desirable target in RA treatment. Given the multiple functions of CCR5, redundancies in the chemokine system, and patient selection in the trial, we overview the recent understanding for chemokine receptor blockade in the treatment of RA

引用

页数：2